Herantis Pharma Plc's Board of Directors resolved on a rights issue and publishes the terms and conditions of the rights issue
Herantis Pharma PlcCompany release, 3 May 2022 at 11:20 a.m. EEST THE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Herantis Pharma Plc ("Herantis" or the "Company"), an innovative biotech company developing new disease modifying therapies for Parkinson's disease, announced on 29 March 2022 that it is planning a directed share issue and a rights issue